This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
home:diseases:ibs [02.10.2019] – [Higher temporal instability] sallieq | home:diseases:ibs [03.15.2019] – [Further research] sallieq | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Irritable bowel syndrome (IBS) ====== | ====== Irritable bowel syndrome (IBS) ====== | ||
+ | |||
+ | < | ||
Line 45: | Line 47: | ||
Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | ||
+ | |||
+ | ==== Further research ==== | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
+ | |||
+ | Mast cell activation syndromes | ||
+ | |||
+ | Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease. | ||
+ | |||
+ | Mast cells are located in close proximity to the vasculature, | ||
+ | |||
+ | Mast cell activation plays an important role in stress-mediated disease pathogenesis. | ||
+ | |||
+ | |||